Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10241 Phase 1 in Advanced Solid Tumors
NCT04477057Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dalmelitinib in solid tumor, sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity at 21 days and Maximum Tolerated Dose at 21 days. Status: unknown.
02
Drugs
dalmelitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04477057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04477057.